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THE MISINTERPRETATION OF THE PATENT EXHAUSTION
DOCTRINE AND THE TRANSGENIC SEED INDUSTRY IN LIGHT OF
QUANTA V. LGELECTRONICS
Tod Michael Leaven'
The Supreme Court's recent interpretation of the patent
exhaustion doctrine mandates that the transgenic seed industry use
contract law instead ofpatent law to enforce post-sale restrictions.
Prior to Quanta Computer, Inc. v. LG Electronics, Inc., the federal
district courts and the Federal Circuit held that patent exhaustion
was not triggered if a sale was restricted and that post-sale
restrictions are enforceable under federal patent law. In Quanta,
the Court held that all authorized sales trigger patent exhaustion
regardless of restrictions and that post-sale restrictions are not
enforceable under patent law. Although Quanta is a case about
computer components, the Court's decision affects the transgenic
seed industry. Both the computer industry and the transgenic seed
industry relied heavily upon the same pre-Quanta federal case law
for interpretation of the patent exhaustion doctrine. This broad
holding removes uniform federal remedies under patent law for
violating post-sale restrictions, and the seed industry must now
rely on a patchwork of state contract law to enforce post-sale
restrictions.
I. INTRODUCTION
On June 9, 2008, the Supreme Court of the United States
unanimously clarified the patent exhaustion doctrine2 in Quanta
Computer, Inc. v. LG Electronics, Inc.' The patent exhaustion
1 J.D. Candidate, University of North Carolina School of Law, 2010.
2 The patent exhaustion doctrine states that an authorized sale of a patented
article "exhausts the monopoly in that article and the patentee may not
thereafter, by virtue of his patent, control the use or disposition of the article."
United States v. Univis Lens Co., 316 U.S. 241, 250 (1942) (citing Bloomer v.
McQuewan, 55 U.S. (1 How.) 539, 549-50 (1853)).
128 S. Ct. 2109 (2008).
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doctrine sets the threshold for when a patent is considered
exhausted, meaning the patentee or a licensed agent can no longer
exert control over the patented item and the purchaser of the item
may use it in any manner without any threat of committing patent
infringement.' In Quanta, the Court held that the initial
authorized' sale of a patented item terminates all of the patent
rights to that item.' The Court claimed that its holding simply
reaffirmed the interpretation it has held since the Nineteenth
Century.' The decision firmly disavows the federal district courts'
and the Federal Circuit's misinterpretation that only an
unrestricted' sale could exhaust the patentee's rights over an item.'
4 Id. at 2115.
In Quanta, the term "authorized sale" can be defined as a sale where the
seller does not violate terms or conditions at the time of the sale. See id. at 2122
(stating that exhaustion turns on Intel's license to sell and not on Quanta's
decision to obey contractual restrictions). Whether or not the buyer is in any
violation of any provisions, or intends to violate any provision, has no effect on
whether the sale is authorized. See id.
6 Id.
7 Id. at 2113. Though the Supreme Court said they were simply reaffirming
their past holdings, the Court has stated that triggering patent exhaustion has
been conditioned upon an unconditional sale as opposed to an authorized sale
since Bloomer v. McQuewan, 55 U.S. (1 How.) 539 (1853), the first time the
Court addressed patent exhaustion. See Motion Picture Patents Co. v. Universal
Film Mfg. Co., 243 U.S. 502, 516 (1917) ("[T]he right to vend is exhausted by a
single, unconditional sale, the article sold being thereby carried outside the
monopoly of the patent law and rendered free of every restriction which the
vendor may attempt to put upon it."). Regardless of this history, the Court now
holds that it is an authorized sale. Quanta, 128 S. Ct. at 2113.
8 A "restricted sale" can be defined as any sale that includes conditions or
requirements which must be met by the purchaser. See Monsanto Co. v.
Scruggs, 459 F.3d 1328, 1333 (Fed. Cir. 2006) (describing a sale that limits
farmers' use of the seed they purchased to only a single commercial crop as
restricted). It is possible for a restricted sale to be authorized.
9 See, e.g., Monsanto, 459 F.3d at 1328 (holding that a restricted sale does not
trigger patent exhaustion and that restrictions are within the patent grant); B.
Braun Medical, Inc. v. Abbott Lab., 124 F.3d 1419 (Fed. Cir. 1997) (holding
that the exhaustion doctrine does not apply to an expressly conditioned sale and
that such conditions are subject to patent law); Mallinckrodt, Inc. v. Medipart,
Inc., 976 F.2d 700, 709 (Fed. Cir. 1992) (holding that patent exhaustion is not
triggered by a conditioned sale and that "violation of the restriction may be
remedied by action for patent infringement."). Quanta's holding that patent
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Although Quanta involved computer components, the
ramifications naturally extend to any industry that relies upon the
lower courts' misinterpretation of patent exhaustion.o The Court
issued its decision despite warnings from the transgenic seed"
industry that such a broad holding could have serious adverse
consequences on its industry.12  The Court also noted that the
exhaustion applies even when a sale is restricted is echoed in a treatise that
states that "[w]here the sale of a product is authorized and the exhaustion
doctrine applies, an express reservation of rights communicated to the buyer will
not defeat its application." MATTHEW BENDER & CO., INC., LEXIsNEXIs GROUP,
1-2 MILGRIM ON LICENSING § 2.30 (2008).
10 Quanta Computer, Inc. v. LG Electronics, Inc. reversed LG Electronics, Inc.
v. Bizcom Electronics, Inc., 453 F.3d 1364 (Fed. Cir. 2006). Bizcom, which held
that only an unrestricted sale triggers exhaustion, traced its interpretation of the
patent exhaustion doctrine to both B. Braun Medical v. Abbott Lab., 124 F.3d
1419 (Fed. Cir. 1997), and Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700
(Fed. Cir. 1992). Bizcom, 453 F.3d at 1370. B. Braun traced its interpretation to
Mallinckrodt. B. Braun, 124 F.3d at 1426. The major transgenic seed cases also
traced their interpretation of patent exhaustion to either B. Braun or Mallinkrodt,
or both. Scruggs, 459 F.3d at 1336, 1338; Monsanto Co. v. McFarling, 363 F.3d
1336, 1341-42 (Fed. Cir. 2004) ("McFarling Il'); Monsanto Co. v. McFarling,
302 F.3d 1291, 1298-99 (Fed. Cir. 2002) ("McFarling I). The American Seed
Trade Association wrote an amicus curiae brief in Quanta that singled out
Mallinkrodt as the pillar of transgenic seed interpretation of patent exhaustion.
Brief Amicus Curiae of The American Seed Trade Association in Support of
Neither Party at 2-3, Quanta, 128 S. Ct. 2109 (No. 06-937) [hereinafter Seed
Brief] ("If this Court were to reject Mallinckrodt and broadly hold that
conditional sales run afoul of the patent exhaustion/ first sale doctrine, its ruling
could have serious and perhaps unintended adverse consequences.").
" A transgenic seed is produced when a genetic sequence is artificially
introduced into a naturally occurring seed to create a particular trait. Mycogen
Plant Science, Inc. v. Monsanto Co., 61 F. Supp. 2d 199, 207-09 (D. Del. 1999),
aff'd, 243 F.3d 1316 (Fed. Cir. 2001). Transgenic seeds are also commonly
referred to as genetically modified, or GM, seeds. See Felicia Wu & William P.
Butz, The Future of Genetically Modified Crops: Lessons from the Green
Revolution, at 43 (Rand, 2004), available at http://www.rand.org/pubs/
monographs/2004/RANDMG161.pdf.
12 Seed Brief, supra note 10, at 3. The Supreme Court was aware of the
implications this decision would have on the seed industry. During oral
arguments, Justice Kennedy asked, "Are there cases where some downstream
restrictions on use might be necessary to prevent the patent from becoming
worthless, i.e., in the biological area for replication of seeds in agriculture and so
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patentee will have to rely upon contract law instead of patent law
to enforce any post-sale restrictions." The result of the Court's
decision is that members of the transgenic seed industry can no
longer avoid patent exhaustion by using complex licensing and
sales restrictions, a practice upon which they have come to rely.14
Losing uniform patent law remedies" for enforcement of post-sale
restrictions will force the industry to restructure its sales model to
rely on contract law.'" Contract law is controlled at the state level
and is subject to state majoritarian pressure, which, in agricultural
states, might favor farmers over big seed corporations." With the
growing importance of the transgenic seed industry," this shift to
contract law could translate into higher food and energy costs as
well as delay several benefits that transgenic crops provide.
forth?" Transcript of Oral Argument at 15-16, Quanta, 128 S. Ct. 2109 (No.
06-937).
'3 Quanta, 128 S. Ct. at 2121 n.7.
14 See Scruggs, 459 F.3d at 1335-36; McFarling II, 363 F.3d at 1342-43;
McFarling I, 302 F.3d at 1298-99.
1 "In contrast to the limited protections offered by contract law remedies,
patent law allows the inventor of a self-replicating patented crop product to
pursue remedies (including injunctive relief) against anyone who threatens to
make or sell the product in competition with the patentee." Brief for Croplife
International as Amicus Curiae Supporting Neither Party at 13, Quanta, 128 S.
Ct. 2109 (No. 06-937) (citing 35 U.S.C. §§ 281, 283-85) [hereinafter Croplife
Brief]. Unlike contract law, patent law "provides for treble damages in cases of
willful infringement." Seed Brief, supra note 10, at 21 n.33 (citing 35 U.S.C.
§ 284 and Dowling v. United States, 473 U.S. 207, 227 n.19 (1985)).
16 "Consigning patentees, particularly small biotech companies, to the
vagaries of 50 States' contract laws will deny the biotech industry the stability
and consistency that the federal government itself has acknowledged is critical
to the industry's survival and continued growth." Brief of the BioTechnology
Industry Organization as Amicus Curiae in Support of Neither Party at 31,
Quanta, 128 S. Ct. 2109 (No. 06-937) (citing Federal Trade Commission, To
Promote Innovation: The Proper Balance of Competition and Patent Law and
Policy (Oct. 2003)) [hereinafter Biotech Brief]. Though this recent development
focuses on the transgenic seed industry, Quanta affects all industries that have
relied upon the Federal Circuit's interpretation of the exhaustion doctrine.
17 See David. R. Moeller, State legislative activity of GMOs, 21 Agric. L.
Update 1, 4 (2003), available at http://www.nationalaglawcenter.org/
assets/aala/12-03.pdf.
1 Wu & Butz, supra note 11, at xv-xxiv.
19 See Seed Brief, supra note 10, at 16.
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In a world with global climate change, increased carbon
emissions, drought, poverty, and malnutrition, the transgenic seed
and the bioengineered crop it produces is the deus ex machina,
which translates to "god from the machine."20 Crops can be
engineered to resist insects, drought, diseases, herbicides, salinity,
and cold temperatures, and they can be grown in ways that
decrease wind erosion and water erosion.2 1 It is also possible to
increase nutrition and health benefits 2  as well as crop
production.2 3 Crops can also be engineered to more easily and
efficiently convert into biofuels and bioenergy.24 Engineered crops
20 "God from the machine" refers to a mechanism in Greek plays where an
unwinnable situation or unconquerable foe is conquered by a god who is literally
lifted unto the stage via a machine or crane. The expression is often used when
the god is either artificial or implausible. Thomas G. Chondros, "Deus-ex-
Machina" Reconstruction and Dynamics, in RECONSTRUCTION AND DYNAMICS
INTERNATIONAL SYMPOSIUM ON HISTORY OF MACHINES AND MECHANISMS:
PROCEEDINGS HMM2004 87, 87 (2004).
21 Croplife Brief, supra note 15, at 5-6
22 Id. at 6-7 (citation omitted). Discussing the increased nutrition and health
benefits of transgenic seeds as follows:
[H]undreds of thousands of children in developing countries suffer
from blindness caused by Vitamin A deficiency, and more than one
billion women suffer from iron deficiency anemia, because traditional
food sources such as rice do not supply enough of these nutrients. But
with the support of CropLife member Syngenta, scientists have
developed "Golden Rice" that is bioengineered to produce iron and
beta carotene (which is converted to Vitamin A by the body). One
study estimates that the health and welfare benefits of Golden Rice
varieties in the Philippines alone could exceed $100 million. Other
scientists are developing bioengineered plant varieties that contain
increased amounts of healthy antioxidants and omega-3 fatty acids,
decreased amounts of harmful saturated fats, and even vaccines to
prevent cervical cancer.
Id.
23 Id. at 5 (describing health benefits and increased crop production).
24 See Targeted Growth, Inc., http://targetedgrowth.com (last visited Nov. 5,
2008) (on file with the North Carolina Journal of Law & Technology). Targeted
Growth is a biotech company which heralds itself as "a crop biotechnology
company focused on developing products with enhanced yield and improved
quality for the agriculture and energy industries." Id. The ability to convert
crops into biofuels and bioenergy more easily is discussed at
http://targetedgrowth.com/pages/Technologies/Core-Technologies (last visited
Nov. 5, 2008) (on file with the North Carolina Journal of Law & Technology).
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can also encompass vaccines against cholera and hepatitis B.25 In
the United States, farmers grow genetically modified varieties of
corn, canola, cotton, papaya, squash, and soybeans.2 6 In 2005,
bioengineering had increased crop production by 8.3 billion
pounds. 27  At the same time, bioengineering also reduced both
costs by $1.4 billion and pesticide use by 69 million pounds.28 In
discussing the seed industry's reliance upon the lower federal
courts' case law, Croplife International, "a global federation
representing the plant science industry and a network of regional
and national associations in 91 countries,"29 explains:
[Transgenic seed patentees] commercialize such products using limited
licenses that allow growers to raise and sell one generation of crops, but
not to save and replant the resulting crops to make subsequent
generations of the patented product. [Seed patentees] rely upon settled
case law holding that the patent exhaustion doctrine does not invalidate
such license limitations. 30
Part II of this recent development describes the transgenic seed
industry and how the federal district courts and the Federal Circuit
applied the patent exhaustion doctrine to the industry. Then the
seed industry will be compared to a strikingly similar case
involving licensing and patent exhaustion in the computer
industry." This comparison is important for two reasons. First,
the computer patent exhaustion case LG Electronics, Inc. v. Bizcom
Electronics, Inc.,3 2 relies upon the same district and circuit court
precedent as do the transgenic seed cases. Second, Quanta
reversed Bizcom due to the lower courts' misinterpretation of the
patent exhaustion doctrine. Part III of this recent development
analyzes the impact that the exhaustion doctrine will have upon the
transgenic seed industry after Quanta overruled the lower courts'
25 Wu & Butz, supra note 11, at xix.
26 Croplife Brief, supra note 15, at 4.
27 Id. at 5-6.
28 Id.
29 Croplife International, http://www.croplife.org (last visited November 2,
2008) (on file with the North Carolina Journal of Law and Technology).
30 Croplife Brief, supra note 15, at 2.
3 LG Electronics, Inc. v. Bizcom Electronics, Inc., 453 F.3d 1364 (Fed. Cir.,
2006), rev'd, Quanta, 128 S. Ct. 2109 (2008).
32 Id.
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interpretation. Finally, Part IV of this recent development briefly
examines how the Supreme Court's decision requires reliance upon
contract law instead of patent law."
II. CASE LAW BEFORE QUANTA
A. Transgenic Seed Industry
The sales and contracting model used by the transgenic seed
industry is based upon years of seemingly settled federal case law.
Seed patentees own patents for numerous biotechnologies and
license these biotechnologies to seed companies.3 4 The seed
companies are licensed to manufacture35 and sell seeds
incorporating the patented technologies to farmers on the condition
that the seed companies "place a notice on all bags of [transgenic]
seeds stating that the seeds are covered by U.S. Patents, that the
purchase of the seeds conveys no license, and that a license from
[the seed patentee] must be obtained before using the seeds."3 6
The license between the seed patentee and the farmer regulates the
first-generation seed" by requiring the farmer to only use the seeds
for one commercial crop season.3 8 The license further regulates
3 The availability of contract law was only noted in Quanta, 128 S. Ct. at
2122 n.7, but it is explicitly spelled out in Bloomer v. McQuewan, 55 U.S. (1
How.) 539, 549-50 (1853).
34 See, e.g., Monsanto Co. v. Scruggs, 459 F.3d 1328, 1333 (Fed. Cir. 2004).
3 Manufacturing usually consists of introducing the patented genetic material
into an unpatented seed's genetic code. Wu & Butz, supra note 11, at 40.
36 Scruggs, 459 F.3d at 1336. This notice upon a bag of seeds has been
referred to as a seedwrap license, even though it purports to carry no license
itself. See Ryan Crawford, Did I Save My Seed for This? United States
Intellectual Property Law, the Continuing Shift in Protection from Growers to
Developers, and Some Potential Implications for Agriculture, SYRACUSE SCI. &
TECH. L. REP. Spring 2006, http://justice.syr.edu/sstlr/wp-content/uploads/did-i-
save-my-seeds-for-this.pdf, at 2, (on file with the North Carolina Journal of Law
& Technology).
3 The seeds initially purchased by the farmers from the seed companies are
known in the industry as first-generation seeds. The plants grown from the first-
generation seeds produce a new generation of seed known as second-generation
seeds.
3 Scruggs, 459 F.3d at 1332.
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the second-generation seed39 by stating that the farmer must
commercially sell all of the second-generation seed and cannot
save any second-generation seed for either personal consumption
or replanting.40 Seed patentees utilize this contractual procedure
for securing the continuance of their patent rights post-sale.41
When farmers violate these restrictions by saving and planting
second-generation seeds, seed patentees protect their interests by
bringing patent infringement suits against the farmers.4 2  In
defending such suits, farmers assert, applying the patent exhaustion
doctrine, that the seed patentees cannot exert control over the seeds
because the seeds were sold outright, moved out from under the
patent monopoly, and belong entirely to the farmers.43 In response,
seed patentees generally rely upon three major arguments under
patent law to enforce the restrictions against using second-
generation seeds: (1) in order for a sale to trigger patent
exhaustion, it must be an unrestricted sale and the licensing
requirements for purchasing seed make these sales restricted;44 (2)
the rights of seed patentees are severable and the seed patentees are
only conveying certain rights and not others;45 and (3) patent
3 See supra notes 36 and 37.
40 id.
41 Croplife Brief, supra note 15, at 2. Although it is a contractual procedure,
the contracts are being enforced with patent law alongside of contract law. Id.
42 See, e.g., Scruggs, 459 F.3d at 1328.
43 See, e.g., id at 1335-36.
44 When farmers argue that they are entitled to use the seeds in an
unencumbered fashion under the doctrine of patent exhaustion, the district and
circuit courts have held patent exhaustion inapplicable because the sale was
restricted. See e.g., id. The federal courts relied upon Mallinckrodt, which held
that "violation of the [post-sale] restriction may be remedied by action for patent
infringement." Mallinckrodt v. Medipart, 976 F.2d 700, 709 (Fed. Cir. 1992).
45 Citing the Supreme Court, the district and circuit courts held that the
patentees may sever their patent interests and convey them piecemeal because
"[t]he right to make, the right to sell, and the right to use may be granted or
conferred separately by the patentee." Brulotte v. Thys Co., 379 U.S. 29, 31
(1964) (citing Adams v. Burke, 84 U.S. 453, 455 (1873)) (quotations omitted).
The lower federal courts held that this severability means the patentee can
convey the right to use the first-generation seeds, but not the right to make new
seeds. See Monsanto Co. v. McFarling, 302 F.3d 1291, 1299 (Fed. Cir. 2002)
(holding that "[t]he price paid by the purchaser reflects only the value of the
'use' rights conferred by the patentee."); Jazz Photo Corp. v. Int'l Trade
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exhaustion only applies to first-generation seeds and not the
second generation.46 Due to the reliance on the lower courts'
misinterpretation of patent exhaustion, the transgenic seed cases
are analogous to Bizcom, which involves computer component
patents.
B. LG Electronics, Inc. v. Bizcom Electronics, Inc.
In Bizcom, a computer industry case with sales and licensing
arrangements strikingly similar to those in the transgenic seed
industry, the sales and contracting model used was also based upon
the same seemingly settled federal case law. LG Electronics, Inc.
("LG") owned patents for numerous technologies relating to
personal computers and licensed the technologies to Intel, Inc.
("Intel"). " Intel is licensed to manufacture microprocessors and
chipsets incorporating the patented technologies and sell them to
Quanta Computers, Inc. ("Quanta") and other companies on the
condition that they give written notice that the purchase of the
patented items conveys no license, that Quanta does not have a
license to combine an Intel product with any non-Intel product, and
that Quanta further has to obtain a license from LG. 48 LG utilizes
this contractual procedure to secure the continuance of its patent
rights post-sale.49
Comm'n, 264 F.3d 1094, 1102 (Fed. Cir. 2001) (stating that "the ownership of a
patented article does not include the right to make a substantially new article.").
46 See, e.g., McFarling, 302 F.3d at 1299. Some courts have held that even if
patent exhaustion applied, it would only apply to first-generation seeds and not
to second-generation seeds because "[w]ithout the actual sale of the second
generation seed to [the farmer], there can be no patent exhaustion" regarding the
second generation of seeds. Scruggs, 459 F.3d at 1336.
47 LG Electronics, Inc. v. Bizcom Electronics, Inc., 453 F.3d 1364, 1368 (Fed.
Cir. 2006), cert. granted, 128 S. Ct. 28 (2007).
48 Quanta Computer, Inc., v. LG Electronics, Inc., 128 S. Ct. 2109, 2114
(2008).
49 See Brief for Plaintiff-Appellant LG Electronics, Inc. at 2, LG Electronics,
Inc. v. Bizcom Electronics, Inc., 453 F.3d 1364 (Fed. Cir. 2006) (No. 05-1261)
[hereinafter Plaintiffs Brief] (explaining how the licensing arrangement is
designed to toll patent exhaustion). As with the transgenic seed cases, patent
law is utilized to enforce the contractual arrangements. Id.
FALL 2008] 127
N.C. J.L. & TECH.
When Quanta violated this restriction by purchasing the
patented items and combining them with non-Intel components,"o
LG sued Quanta for patent infringement." The Federal Circuit
relied upon three arguments to reverse the district court's order and
sustain LG's restrictions under patent law: (1) only unrestricted
sales trigger patent exhaustion, 2 (2) LG's rights are severable and
LG did not convey all of its rights,53 and (3) patent exhaustion only
applies to the physical items and not to the method of combining
those items with other components.54
5o There was an express restriction against combining the patented
components made by Intel with non-Intel components. Id. at 8-18.
5' LG Electronics, Inc. v. Asustek Computer, Inc., 2002 U.S. Dist. LEXIS
25956 (N.D. Cal. 2002); see also LG Electronics, Inc. v. Bizcom Electronics,
(No. C 01-1375 CW, C 01-1594 CW, C 01-2187 CW, C 01-1552 CW) 2004
U.S. Dist. LEXIS 29906 (N.D. Cal. Nov. 30, 2004).
52 The court held the exhaustion doctrine "does not apply to an expressly
conditional sale or license." Bizcom, 453 F.3d at 1370. The Federal Circuit has
also held that violations of post-sale restrictions may be remedied by an action
for patent infringement. B. Braun Medical Inc. v. Abbott Laboratories, 124 F.3d
1419, 1426 (Fed. Cir. 1997) (citing Mallinckrodt, Inc. v. Medipart, Inc., 976
F.2d 700, 709 (Fed. Cir. 1992)).
5 By holding that LG conveyed only the right for certain uses and not for
others, the court upheld its precedent of patent right severability. The court
determined LG could convey the right to purchase the microprocessors and
chipsets and use them in a specified manner but could not convey the right to
combine them with non-Intel components. See Bizcom, 453 F.3d at 1370
(stating that the sale of an item does not exhaust the patentee's rights for other
claims associated with the item).
54 Bizcom, 453 F.3d at 1369. This argument was sustained by the district
court and affirmed by the Federal Circuit. The court further held that even if
patent exhaustion were to apply, it would only apply to the actual
microprocessors and not to the method patents. Id. The district court held that
the doctrine of patent exhaustion only applies to apparatus or composition-of-
matter claims that describe operations to make or use a product. Id. at 1368-69.
The Federal Circuit affirmed this decision in that it also held that patent
exhaustion does not apply to method patents. Id. at 1367-70. The decision was
based on Glass Equip. Dev., Inc. v. Besten, Inc., 174 F.3d 1337, 1342 n.1 (Fed.
Cir. 1999) (citing Bandag, Inc., v. Al Bolser's Tire Stores, Inc., 750 F.2d 903,
924 (Fed. Cir. 1984)). Bizcom, 453 F.3d at 1370. Bandag held that a method
patent cannot be exhausted by the sale of an item because the method patent
"claims of the [patentee] are directed to a method [of use] and cannot read on
the equipment." Bandag, 750 F.2d at 924 (quotations omitted).
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C. Similarities between the Seed Industry and Bizcom
The immediate similarities between the licensing and sales
restrictions and how they are used to avoid patent exhaustion in
both the transgenic seed industry and the computer industry stem
from their mutual reliance on the same federal case law." One of
the most prominent transgenic seed cases cites Bizcom for the
court's interpretation of the patent exhaustion doctrine." Evidence
of these two industries' reliance on the lower federal courts'
interpretation of the doctrine is evident in how contracts and sales
models are structured in both industries. At the top of the
contracting schemes lie the patent owning entities (LG and seed
patentees such as Monsanto)." These entities license different
vendors (Intel and seed companies) to manufacture and sell items
containing their patented elements." The vendors are required by
contract to inform the purchasers (Quanta and the farmers) that the
vendors themselves do not convey a license to the purchasers to
use the patented products and that the purchasers must seek a
license with the patentees requiring additional royalties.59 In both
industries, purchasers enter into a license agreement with the
patentees post-sale, and, most importantly, both patentees rely on
patent law to enforce the terms of the post-sale licensing
agreements.60
5 In both the transgenic seed cases and Bizcom, the courts rely upon B. Braun
and Mallinckrodt in defining the patent exhaustion doctrine. See generally
Bizcom, 453 F.3d 1364; see, e.g., Monsanto Co. v. Scruggs, 459 F.3d 1328,
1336 (Fed. Cir. 2004).
56 Scruggs, 459 F.3d at 1336.
5 See id. at 1333; Bizcom, 453 F.3d at 1368.
8 See Scruggs, 459 F.3d at 1333; Bizcom, 453 F.3d at 1368.
59 See Scruggs, 459 F.3d at 1333, 1335 (stating that a seed grower is required
to inform the farmer that he must sign a license agreement with the seed
patentee); Plaintiffs Brief, supra note 49, at 22-23 ("Intel notified them that
they could not obtain that license simply by buying Intel components" and
"[t]hey knew in advance that purchasing Intel components was just their first
step-that they would need a license from LGE to use the components in
infringing computers made for the U.S. market.").
60 Scruggs, 459 F.3d at 1336; Plaintiff s Brief, supra note 49, at 23.
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III. QUANTA COMPUTER, INC. v LG ELECTRONICS, INC., AND
BEYOND
A. General
In Quanta Computer, Inc. v. LG Electronics, Inc.,61 the
Supreme Court unanimously held that the initial authorized sale of
an item discharges all of the patent rights over that item.62
According to the current Supreme Court interpretation of the
patent exhaustion doctrine: (1) a patentee cannot bring a patent
infringement suit against a purchaser for violating a post-sale
restriction; (2) when a patented item is sold, the patentee receives
compensation and thus loses all rights to that item, while the
purchaser gains the right to use the item to its fullest extent;' (3)
patent exhaustion is triggered by an authorized sale, not an
unrestricted sale;" (4) a patent monopoly has separate severable
rights, some trigger exhaustion and some do not;66 and (5) if a
particular patent, such as a method patent, embodies the use of an
article, the sale of the article automatically exhausts the patent,
even if the patent itself was never sold.67
B. Post-Sale Restrictions
Quanta specifically addressed the Court's previous dismissal
of a patent holder's suit alleging that a licensee violated post-sale
restrictions and then reaffirmed this dismissal." Quanta also cited
6 128 S. Ct. 2109 (2008).
62 Quanta Computer, Inc. v. LG Electronics,Inc., 128 S. Ct. 2109, 2115
(2008).
63 Id.
6 Adams v. Burke, 84 U.S. 453, 455-56 (1873).
65 Quanta, 128 S. Ct. at 2121 (citing United States v. Univis Lens Co., 316
U.S. 241, 249 (1942)).
66 Bloomer v. McQuewan, 55 U.S. (1 How.) 539, 549 (1853) (discussing the
differences between "make and vend" and "use" rights and how conferring
"make and vend" rights is usually a license that does not trigger patent
exhaustion but conferring "use" rights is usually a sale that does trigger patent
exhaustion).
67 Quanta, 128 S. Ct. at 2113.68 Id. at 2115 (citing Adams, 84 U.S. at 455) ("[T]he Court affirmed the
dismissal of a patent holder's suit alleging that a licensee had violated postsale
restrictions . . .").
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Henry v. A. B. Dick Co.,"9 the only case where a post-sale
restriction was held valid under patent law, which had since been
overruled.o Henry held that any reasonable stipulation that was
not "inherently violative" of a law was enforceable." The only
requirement in Henry was that the purchaser must have had notice
that the purchase was made with only a "qualified right of use."72
Henry further stated that the stipulation can be upheld through
contract law as well as patent law.73 Ironically, although this
language was overruled more than ninety years ago, this is the
same reasoning used by the lower court in Bizcom.74 Monsanto
Co. v. McFarling," a recent transgenic seed case, also used this
reasoning." The American Seed Trade Industry relied upon this
same reasoning in its argument in support of protecting transgenic
seed patents from the exhaustion doctrine in an amicus curiae brief
it filed in Quanta." In specifically mentioning Henry and its
overruling, the Court held post-sale restrictions are not to be
enforced by patent law."
The result of the holding in Quanta means that LG loses its
ability to use patent law to remedy Quanta's violation of the post-
69 224 U.S. I (1912).
70 Quanta, 128 S. Ct. at 2115-16. The A. B. Dick Company sold a patented
machine with an attached license stipulating that the machine could be used only
with supplies made by the A. B. Dick Company. Henry, 224 U.S. at 11. Henry
was explicitly overruled in Motion Picture Patents Co. v. Universal Film Mfg.
Co., 243 U.S. 502, 518 (1917).
71 Henry, 224 U.S. at 31.
72 Id. at 26.
73 Id. at 31.
74 LG Electronics, Inc. v. Bizcom Electronics, Inc., 453 F.3d 1364, 1370
(2006).
7 302 F.3d 1291 (2002).
76 Id. at 1298 ("[U]se of a patented product in violation of a valid restriction
may be remedied under the patent law." (citing Mallinckrodt, Inc. v. Medipart,
Inc., 976 F.2d 700, 701 (Fed. Cir. 1992)) (quotations omitted)).
7 See Seed Brief, supra note 10, at 17 ("[T]he rule is, with few exceptions,
that any conditions which are not in their very nature illegal with regard to th[e]
kind of property [at issue], imposed by the patentee and agreed to by the
licensee ... will be upheld by the courts." (citing E. Bement & Sons v. National
Harrow Co., 186 U.S. 70, 91 (1902))).
78 Quanta Computer, Inc. v. LG Electronics, Inc., 128 S. Ct. 2109, 2115-16
(2008).
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sale restrictions on its patented components." For the transgenic
seed industry, this means seed patentees can no longer rely upon
patent law to seek redress for a farmer's violation of the post-sale
restrictions placed upon its patented seeds."o In Quanta, the Court
stated that "the primary purpose of our patent laws is not the
creation of private fortunes for the owners of patents but is 'to
promote the progress of science and useful arts.'""' This statement
in Quanta signals the Court's intent to view the Patent Clause of
the Constitution82 as erring on the side of utilitarianism, thus
hoping to enrich the collective knowledge of society" instead of
simply promoting the natural rights of the inventor.84
79 Quanta, 128 S. Ct. at 2122 (describing LG's License Agreement as a post-
sale restriction).
80 See Croplife Brief, supra note 15, at 2-3 (describing seed patentee's license
agreements as post-sale restrictions).
81 Quanta, 128 S. Ct. at 2116 (citing Motion Picture Patents Co. v. Universal
Film Mfg. Co., 243 U.S. 502, 509 (1917)).
82 U.S. CONST. art. I, § 8 ("The Congress shall have Power ... To promote
the Progress of useful Arts . . . by securing for limited Times to . . . Inventors the
exclusive Right to their . .. Discoveries.").
83 For an argument favoring the granting of patent monopolies for the
betterment of society, see Rebecca S. Eisenberg, Patents and the Progress of
Science: Exclusive Rights and Experimental Use, 56 U. CHI. L. REv. 1017,
1024-28 (1989). Thomas Jefferson, founding father and the first patent
administrator, supported utilitarianism over natural rights in his letter to Isaac
McPherson:
It has been pretended by some . . . that inventors have a natural and
exclusive right to their inventions.. .. If nature has made any one thing
less susceptible than all others of exclusive property, it is the action of
the thinking power called an idea . ... Its peculiar character, too, is that
no one possesses the less, because every other possesses the whole of
it. He who receives an idea from me, receives instruction himself
without lessening mine; as he who lights his taper at mine, receives
light without darkening me. That ideas should freely spread from one
to another over the globe, for the moral and mutual instruction of man,
and improvement of his condition, seems to have been peculiarly and
benevolently designed by nature . . .. Inventions then cannot, in nature,
be a subject of property. Society may give an exclusive right to the
profits arising from them, as an encouragement to men to pursue ideas
which may produce utility, but this may or may not be done, according
to the will and convenience of society, without claim or complaint from
anybody.
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C. Full Use
Quanta cited several cases which held that the sale of a
patented item by the patentee or an authorized agent gives the
patentee his consideration, or financial gain, and the patentee thus
parts with the right to restrict the use of the patented item." The
Court further held that the patented item carries with it the right to
use the item "to the full extent to which it can be used." 86 In
Quanta, the patented item's full extent of use includes combining
the patented items with non-Intel components." The value of the
patented components is in their use," and Intel was authorized to
sell the patented components;89 therefore, LG parted with the right
to restrict the patented component's use under patent law.
Likewise, in the transgenic seed cases, the seed's full extent of
use includes not only selling the crop, but also replanting the
seeds.o The value of the patented seeds is in their use,9 1 and the
seed companies are authorized by the patentees to sell the seeds;9 2
therefore, the seed patentees part with their right to restrict the
seed's use under patent law.
Michael R. Taylor & Jerry Cayford, American Patent Policy, Biotechnology,
and African Agriculture: The Case for Policy Change, 17 HARV. J.L. & TECH.
321, 338-39 (2004) (citing Thomas Jefferson's letter to Isaac McPherson).
Letter from Thomas Jefferson to Isaac McPherson (on file with the North
Carolina Journal of Law & Technology), available at http://etext.virginia.edu/
etcbin/toccer-new2?id=JefLett.sgm&images=images/modeng&data=/texts/
english/modeng/parsed&tag-public&part-218&division=div1.
84 For an argument favoring the natural rights of the inventor, see A. Samuel
Oddi, Un-Unified Economic Theories ofPatents-The Not-Quite-Holy Grail, 71
NOTRE DAME L. REV. 267, 273-74 (1996).
85 Quanta, 128 S. Ct. at 2115 (citing Adams v. Burke, 84 U.S. 453, 456
(1873)).
1 Burke, 84 U.S. at 455.
87 Quanta, 128 S. Ct. at 2114.
88 See id. at 2120. There is no other use for the patented items except for
combining them with other components, and this is the source of their value. Id.
89 Id. at 2114.
90 See Monsanto Co. v. McFarling, 363 F.3d 1336, 1342 (Fed. Cir. 2004)
(describing how, after planting the first-generation seed and producing a harvest,
both selling and replanting of the harvest are practical uses).
9' See id. (agreeing that the use of agricultural transgenic seeds is to plant
them so that they grow into mature plants).
92 See, e.g., Monsanto Co. v. McFarling, 302 F.3d 1291, 1293 (2002).
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D. Authorized, not Unrestricted, Sale
Quanta proclaimed that the Supreme Court has continuously
held that patent exhaustion is triggered by an authorized sale."
Disavowing the interpretation by the lower courts, Quanta held
that as long as a sale is authorized, the fact that it is restricted has
no bearing upon patent exhaustion.9
LG argued that the sale to Quanta was not authorized because
Intel was unable to convey to Quanta what they both knew Intel
was not authorized to sell, e.g., the right to practice the patents
with non-Intel parts." The district court and Federal Circuit
agreed with LG's argument.9 6 The Supreme Court, however, held
that this argument was faulty because Intel's authority to sell the
products was not conditioned upon Quanta's decision to act in
accordance with LG's directions in the written notice.9 7 The Court
held that Intel's sale to Quanta was authorized, the sale took its
products outside the scope of the patent monopoly, and LG could
no longer assert its restrictions against Quanta by way of patent
law.98
Regarding the transgenic seed industry, the Federal Circuit has
held that a sale to a farmer was not authorized because the seed
distributors lacked the authority to convey a right that both parties
knew could not be conveyed.99 As with Intel, the seed company's
authority to sell its products containing the Monsanto patents is not
conditioned on the farmer's decision to abide by Monsanto's
directions.'" The seed company's sales to the farmers are
authorized'O' and the sales to the farmers should take the seeds
9 Quanta, 128 S. Ct. at 2121 (citing United States v. Univis Lens Co., 316
U.S. 241, 249 (1942)).
94 See id.
95 Id
96 LG Electronics, Inc. v. Bizcom Electronics, Inc., 453 F.3d 1364, 1370
(2006).
9 Quanta, 128 S. Ct. at 2122.
98 Id.
9 Monsanto Co. v. Scruggs, 459 F.3d 1328, 1336 (Fed. Cir. 2004), cert.
denied, 127 S. Ct. 2062 (2007).
'* See id.
'1 Monsanto Co. v. McFarling, 302 F.3d 1291, 1293 (2002).
134 [VOL. 10: 119
Quanta P. LG
outside the scope of the patent monopoly; as a result, the patentee
can no longer assert its patent rights against the farmers.
Some lower courts continue to interpret this portion of the
patent exhaustion doctrine incorrectly, even though this
interpretation was overruled by the Supreme Court.10 2 Other courts
have embraced Quanta.'o3 At least one legal scholar has observed,
"Quanta does not prevent a patentee from enforcing its rights when
a manufacturing licensee sells articles in violation of express
restrictions in its licensing agreement. Such sales would not be
authorized sales."' 04 The importance here is placed on whether the
licensee is in violation of restrictions upon sales, not whether the
purchaser fails to adhere to post-sale restrictions.' She concludes
that "Quanta does not appear to undermine the Federal Circuit's
decision in Monsanto Co. v. McFarling ... which upheld a finding
of patent infringement where a farmer saved and replanted seeds
from a harvest that was grown from patented seeds, in violation of
an express condition of his licensing agreement."0 6 There is a
contradiction here in that in McFarling I and II, the licensee was
not in violation of any restriction during sales, but rather the
purchaser, or farmer, violated restrictions postsale. o' Quanta
102 "The unrestricted sale of a patented article, by or with the authority of the
patentee, 'exhausts' the patentee's right to control further sale and use of that
article by enforcing the patent under which it was first sold." Fujifilm Corp. v.
Benun, No. 05-18632008, U.S. Dist. LEXIS 49719, at *14 (D.N.J. June 30,
2008) (citing Jazz Photo Corp. v. ITC, 264 F.3d 1094, 1105 (2001)) (emphasis
omitted).
103 "The exhaustion doctrine prohibits patent holders from selling a patented
article and then invoking patent law to control postsale use of the article."
Excelstor Tech., Inc. v. Papst Licensing Gmbh & Co. KG, 2008 U.S. App.
LEXIS 19570, at *5 (Fed. Cir. Sept. 16, 2008) (citing Quanta, 128 S. Ct. at
2122) (quotations omitted).
'04Mary LaFrance, The Supreme Court's Broad Interpretation of Patent
Exhaustion in Quanta Computer, Inc. v. LG Electronics, Inc., LexisNexis Expert
Commentary, (Oct. 19, 2008).
"o See id.
106 Id. (citation omitted).
'
0 7 See Monsanto Co. v. McFarling, 363 F.3d 1336, 1338-40 (2004);
Monsanto Co. v. McFarling, 302 F.3d 1291, 1293 (2002).
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stated that "exhaustion turns only on [the licensee's] own license to
sell products practicing the . . . Patents."'"
E. Rights under Patent Law
Quanta discussed Bloomer v. McQuewano' and how the 1853
holding still applies today."'o McQuewan held that two different
conveyable and severable patent rights exist."' These two rights,
as applicable to both LG and transgenic seed patentees, are the
"make and vend" rights and the "use" rights. 12 The "make and
vend" rights are rights that are subject to the limitations of a
license."' These rights allow a licensee to purchase "a portion of
the franchise which the patent confers," but do not allow a licensee
to enjoy any rights that are not purchased." 4 MCQuewan stated
that the purchase of an item with the intent of using it is
completely different.' ' Under the "use" rights:
When the machine passes to the hands of the purchaser, it is no longer
within the limits of the monopoly. It passes outside of it, and is no
longer under the protection of the act of Congress. And if his right to
the implement or machine is infringed, he must seek redress in the
courts of the State, according to the laws of the State and not in the
courts of the United States, nor under the law of Congress granting the
patent." 6
In concluding that the machine is no longer protected by Congress,
but instead is protected by the laws of a state, the Court concluded
that state contract law, not federal patent law, controls."'
Typically, the rights the patentee conveys to the manufacturer and
'08 Quanta, 128 S. Ct. at 2122 (emphasis added).
'o9 55 U.S. (1 How.) 539 (1853). McQuewan was the first case where the
Supreme Court applied the patent exhaustion doctrine. Id.
"o Quanta, 128 S. Ct. at 2115.
"' McQuewan, 55 U.S. at 549.
112 id
113 Id.
114 Id.
115 Id. ("But the purchaser of the implement or machine for the purpose of
using it in the ordinary pursuits of life, stands on different ground.").
116 id.
"' Id. The Court explicitly returns to the availability of contract law later in
the opinion. Quanta Computer, Inc. v. LG Electronics, Inc., 128 S. Ct. 2109,
2122 n.7 (2008).
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seller of the patented items would consist of the "make and vend"
rights, while the rights conveyed to the purchaser would be the
"use" rights. For Bizcom, this means that Intel possessed the
"make and vend" rights and Quanta purchased the "use" rights."'
Under McQuewan, LG's rights to restrict Quanta's use of the
patented items are no longer enforceable under its patent
monopoly; instead, LG has to rely upon state law to seek
compensation." 9 For the transgenic seed industry, this means the
seed companies possess the "make and vend" rights and the
farmers possess the "use" rights.12 As with LG, the transgenic
seed patentee's rights will no longer be enforceable under its patent
monopoly and the patentee will have to rely upon contract law.'2 '
The transgenic seed industry claims that the authority to use an
item does not confer the authority to create a new item.'22 As
previously discussed, the seed patentee can claim that a purchaser
who has the "use" rights is infringing upon a patent by
manufacturing a new patented item.' However, the Federal
Circuit stated that a farmer "plants and grows the first-generation
seed in an identical fashion whether he intends to sell the second-
generation seed as a commercial crop for consumption or whether
he intends to replant it."' 24 The seed patentees cannot claim that
the farmer has infringed upon their patent when he grows a crop
and sells it, yet this is the exact same manufacturing procedure as
" See LG Electronics, Inc. v. Bizcom Electronics, Inc., 453 F.3d 1364, 1368
(Fed. Cir. 2006) (stating that Intel is authorized to manufacture and sell the
patented items and that the defendants purchased the items for use).
"9 Quanta, 128 S. Ct. at 2122 n.7. After holding that LG cannot rely upon
patent law due to the exhaustion doctrine, the Court also suggests that LG can
seek redress under contract law. Id.
120 Patentees are authorized to manufacture and sell the patented seeds. See,
e.g., Monsanto Co. v. McFarling, 302 F.3d 1291, 1293 (Fed. Cir. 2002). The
farmers purchase the right to use the patented seeds. See, e.g., id.
121 The transgenic seed industry warns that if patentees cannot rely upon
patent law due to the exhaustion doctrine, they will have to rely upon contract
law. See Seed Brief, supra note 10, at 21; Croplife Brief, supra note 15, at 12;
Biotech Brief, supra note 16, at 29.
122 Seed Brief, supra note 10, at 18 (citing Hewlett-Packard v. Repeat-O-Type
Stencil Mfg. Co., 123 F.3d 1445, 1451 (Fed. Cir. 1997)).
123 See Bloomer v. McQuewan, 55 U.S. (1 How.) 539, 549 (1852).
124 Monsanto Co. v. McFarling, 363 F.3d 1336, 1342 (2004).
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when he grows a crop for replanting. One way to square the
Supreme Court's precedent with allowing the farmer to
simultaneously use the seed and make new seed is to hold that the
farmer has been given both "use" rights and "make and vend"
rights. This is impractical, however, since it would allow the
farmer to introduce the patented genetic material into the genetic
code of other seeds and share in the monopoly franchise.125
Another way to allow the farmer to grow a crop would be to hold
that "making" new seeds is a part of the "use" right.
Since a farmer cannot use the first generation of seed without
making a second generation, incorporating the act of making the
second generation into the "use" rights of the first generation
seems to be the most plausible rationalization. An analogy can be
drawn between this and a method patent claim. Quanta holds that
when a use is embodied in a product, the right to that particular use
is inseparable and transfers with the product.126 If that use is a
patented method, then that patent is instantly exhausted, even
though the particular patent was never sold, because the item
cannot exist without its embodied use.'2 7 The use of the first-
generation seed is inseparable from the manufacture of second-
generation seed to the extent that the manufacture of the second
generation is actually embodied in the use of the first.128
Therefore, the purchase of the first generation exhausts any patent
infringement associated with manufacturing the second
generation. 129
125 See McQuewan, 55 U.S. at 549 (explaining the privileges associated with
the "make and vend" rights).
126 See Quanta Computer, Inc. v. LG Electronics, Inc., 128 S. Ct. 2109, 2116-
17 (2008) (explaining that an item's only use is embodied within the item and
cannot be severed from the item).
127 See id. at 2122 (stating that an embodied method patent is instantly
exhausted upon the authorized sale of the item that embodies the method).
128 See McFarling II, 363 F.3d at 1342 (implying that it is impossible to use
the first generation of transgenic soybean seed without manufacturing a second
generation of seed).
129 See Quanta, 128 S. Ct. at 2122.
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F. Exhaustion Upon Patents Not Sold
The transgenic seed industry also claims that even if patent
exhaustion applies, it only applies to the first-generation seed
because the second generation was never purchased.130  The
industry claims that patent exhaustion can only apply to items
actually purchased themselves.' 1 As discussed above, Quanta
held that method patents were exhausted even though they were
never sold.'32 The Federal Circuit's holding that patent exhaustion
only applies to the exact item sold has been reversed.
IV. CONTRACT LAW
The transgenic seed industry and the lower courts imply that if
patent exhaustion is not suspended by restrictions, the seed
patentees would not be able to enforce their licensing
agreements.' 34 Uncertainty exists as to whether contract law stands
ready to enforce the rights.' Quanta noted LG needed to pursue a
remedy under contract law.' The Supreme Court has specifically
held that upon sale, a patented item becomes a private and
"individual property, not protected by the laws of the United
States, but by the laws of the State in which it is situated.
Contracts in relation to it are regulated by the laws of the State, and
are subject to State jurisdiction.""' The seed industry argues that
130 See, e.g., Monsanto Co. v. Scruggs, 459 F.3d 1328, 1328 (Fed. Cir. 2006),
cert. denied, 127 U.S. 2062 (2007).
"' See, e.g., id. The "doctrine of exhaustion of the patent right is not
implicated, as the new seeds grown from the original batch had never been
sold." Monsanto v. McFarling, 302 F.3d 1291, 1298-99 (Fed. Cir. 2002).
132 Quanta, 128 S. Ct. at 2122.
133 After Quanta, it has been said that a rule of patent exhaustion is that "[t]he
authorized sale of single product [sic] may exhaust rights in more than one
patent." MATTHEW BENDER & CO., INC., LEXISNEXIS GROUP, 1-2 MILGRIM ON
LICENSING § 2.30 (2008).
134 See, e.g., Seed Brief, supra note 10, at 21 n.33.
135 Reliance upon contract law is discussed in McQuewan as the appropriate
avenue for post-sale restrictions. Bloomer v. McQuewan, 55 U.S. (1 How) 539,
550 (1852). This is again noted in Quanta as well. Quanta, 128 S. Ct. at 2122
n.7.
136 Quanta, 128 S. Ct. at 2122 n.7 ("[T]he authorized nature of the sale to
Quanta does not necessarily limit LGE's other contract rights.").
'37 Bloomer v. McQuewan, 55 U.S. 539, 549 (1853).
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contract law does not afford sufficient protection against the
danger that patented seeds will be transferred to third parties
without authorization and these third parties will then use the seeds
without obtaining a license from the patentee.138 This argument is
without merit since the Supreme Court only referenced contract
law when the patent was exhausted.'39 If there is no authorized
sale, then patent exhaustion is not triggered and the patentee is still
protected from infringement by the third party under patent law.
There are a number of other strategies that can be used in
conjunction with contract law in order to build stronger protection
for the patent holder, such as the Plant Variety Protection Act of
1970 ("PVPA"), 140 price adjusting strategies or trade secrets law,"
product bundling,14 2 and genetic use restriction technologies.'4 3
A concern surprisingly not mentioned in the Quanta amicus
curiae briefs is recent action in state legislatures. Within the last
seven years, state legislators in Missouri and Minnesota introduced
bills allowing farmers to save their seeds regardless of what the
seed patentee and the licensed distributor set forth in contract.'"
138 See, e.g., Croplife Brief, supra note 15, at 12.
1' Quanta, 128 S. Ct. 2109, 2122 n.7 (2008).
140 The Plant Variety Protection Act of 1970 gives up to 25 years monopoly
rights for new, distinct, uniform, and stable sexually reproduced or tuber
propagated plant varieties. 7 U.S.C. §§ 2321-2582 (1980).
1 Increasing prices for the first year "may provide seed companies adequate
return on investment." A. Bryan Endres & Peter D. Goldsmith, Alternative
Business Strategies in Weak Intellectual Property Environments: A Law and
Economics Analysis of the Agro-Biotechnology Firm's Strategic Dilemma, 14 J.
INTELL. PROP. L. 237, 254-68 (2007).
142 This may run afoul of anti-trust laws but is widely practiced by leading
seed corporations. See Monsanto Co. v. McFarling, 302 F.3d 1291 (Fed. Cir.
2002), cert. denied, 537 U.S. 1232 (2003).
143 It is possible to make transgenic seeds that yield infertile crops. An
infertile crop is unable to generate a seed that can grow into a new crop, thus
eliminating the desire to save seed for replanting. Endres & Goldsmith, supra
note 141, at 268.
'"Moeller, supra note 17, at 4. The 2003 Minnesota bill allowed for farmers
that traditionally saved their seed, such as soybean farmers, to continue saving
their seed as long as the seed patentee was compensated. Id. Normally when a
farmer buys seed, the seed price gets severed into two separate parcels: one
portion of the price goes to the licensed seed company that grew the seed
containing the patented genetic material, and the other portion of the price goes
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Legislators in Indiana enacted legislation in 2003 that modified
seed contracts in four ways: (1) "the law mandates that any
disputes under the contracts will be governed by Indiana law, and
any contract clauses that attempt to make disputes subject to
another jurisdiction's laws will not be enforceable;" 4 5 (2) any
forum selection clause must be conspicuous and written near the
farmer's signature; 146 (3) "the law allows communications about
the terms of a seed contract between the farmer, and family
members, attorneys, or business advisors, even if the seed contract
contains a confidentiality provision forbidding such
communications;"l 47 and (4) "the law provides that farmers will
not be liable for breach of a seed contract where a very small or
unintentional presence of a product . . . is found in the farmer's
possession." 48  This legislation could raise concerns about how
much faith seed patentees can place in State governments for their
protection. In tough economic times it could take only one
agricultural state to undermine the entire seed industry.149 Under
to the seed patentee that owns the patent on the genetic material. See Monsanto
Co. v. McFarling, 363 F.3d 1336, 1339 (Fed. Cir. 2004). The Minnesota bill
seems advantageous to both the farmer and the seed patentee. The farmer only
has to pay one portion of the usual seed price (the portion to the patentee and not
to the company that grows the seed) and can save his extra seed instead of
having to buy new seed each year from the seed growing company. The seed
patentee is not only still receiving its compensation, but the reduced cost to the
farmer could mean that additional farmers could now afford the technology and
the seed patentee could receive increased business. However, in McFarling II,
the Court noted that the seed patentee Monsanto also owned twenty percent of
the market of seed growers that distribute the Monsanto seed. Any loss of
profits for the seed growers would also negatively affect the seed patentee
Monsanto. The price of seed in McFarling II was $22.50 for a 50-pound bag
($16.00 for the seed and an additional $6.50 for the technology fee). Id. Under
the Minnesota law, Monsanto would continue to receive $6.50 per bag, but
would lose out on its share of the $16.00 per bag.
145 Moeller, supra note 17, at 4.
146 id.
147 id
148 id
149 If a state that had numerous farmers going bankrupt were to pass a law
allowing the farmers to save their seed and replant it free of charge, then the
contract law that the seed patentees had relied upon would be non-existent in
that state. Unlike federal legislators, who cannot pass bills without support from
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the current sales model for the transgenic seed industry, contract
law is now the only remaining post-sale remedy and, given the
legislative ability to chip away at contracts, that remedy may not
be sufficient.
V. CONCLUSION
Since 1853, the Supreme Court has held that any authorized
sale may trigger patent exhaustion.' The only case to hold that a
post-sale restriction may be enforced under patent law'"' was
explicitly overruled in 1917,152 yet the lower courts have
continuously held to the contrary.'5 3  The lower courts have
erroneously interpreted the patent exhaustion doctrine to be
triggered solely upon unrestricted sales. The transgenic seed
industry relied upon the lower court's precedent, as did the
computer industry.
In reversing Bizcom, Quanta signaled that the patent
exhaustion doctrine still has teeth and industries cannot rely on
patent law to enforce authorized post-sale restrictions. With the
transgenic seed industry's sales models unchanged, the lack of
patent law protection for post-sale restriction leaves the seed
industry relying upon state contract law. Although contract law is
still a viable option for the seed industry, it is evident from state
legislation, such as the 2003 legislation in Indiana, that contract
law is not as stable as patent law. The transgenic seed industry
should either adapt to rely upon contract law, develop a way to
restructure their sales model to receive the protection of another
other federal legislators from different states, state legislators only work within
the realm of their own state. It is plausible that if the farmers in state "A" were
going bankrupt and having to pay high fees to a mega seed-company in state
"B", the state "A" legislators would draft a bill to redress the financial
complaints of state "A's" farmers.
'5 Bloomer v. McQuewan, 55 U.S. (1 How.) 539 (1853).
Henry v. A. B. Dick Co., 224 U.S. 1 (1912).
152 Motion Picture Patents Co. v. Universal Film Mfg. Co., 243 U.S. 502
(1917).
1 Fujifilm Corp. v. Benun, 2008 U.S. Dist. LEXIS 49719 (D.N.J. June 30,
2008).
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law,154 or work out a system where royalties can be combined with
credits for other products tied to the seed purchase to enforce
single-season use and other contractual obligations.'s There is
also hope that these issues with patent exhaustion might be
addressed by the incoming 111th Congress."'
154 Other suggestions have also been proposed such as trade secrets or the
PVPA. The Cato Supreme Court Review suggests that "parties interested in
contracting for a limited patent license may have to first initiate litigation and
then strike deals labeled as settlement agreements instead of patent licenses, in
the hopes of having courts see their contracts more as matters of state contract
law and general federal policy in favor of settling litigation rather than matters
of federal patent policy as potentially controlled by Quanta." F. Scott Kieff,
Quanta v. LG Electronics: Frustrating Patent Deals by Taking Contracting
Options off of the Table?, 2007-08 CATO SUP. CT. REV. 315, 322 (2008). This
journal is misreading the holding in Quanta as "render[ing] void any contract."
Id. at 316.
155 Usually seed contracts include clauses that restrict farmers to only using
pesticides or other products manufactured by the seed patentee. See Monsanto
Co. v. McFarling, 302 F.3d 1291, 1297-99 (Fed. Cir. 2002). If a farmer could
certify that he did not violate any seed-saving provisions, the seed patentee
could offer credits toward purchasing the required pesticides and other materials
the farmer may be contractually obligated to purchase through the seed patentee.
The initial prices of the pesticides and other materials would have to be raised
significantly to induce the desire to obtain these credits.
156 Harold C. Wegner, Post-Quanta, Post-Sale Patentee Controls, 7 J.
MARSHALL REV. INTELL. PROP. L. 682, 700 (2008) ("With the demise of much
needed macroscopic statutory patent reform in the current 110th Congress, it is
inevitable that some form of patent reform legislation will be reintroduced in
2009 in the Congress in the coming 111th Congress.").
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